

Supplementary Appendix:

Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in individuals with insulin-treated type 2 diabetes.

Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G.

Table S1 Anticipated sensor insertion site symptoms

		Open-access Phase Participants (N=139)	
Sign/Symptom	Severity	N subjects	N events
Erythema:	Mild	11	32
	Moderate	10	29
	Severe	1	1
Pain:	Mild	4	4
	Moderate	1	1
	Severe	0	0
Itching:	Mild	9	14
	Moderate	8	28
	Severe	1	1
Rash:	Mild	2	7
	Moderate	3	5
	Severe	0	0
Bleeding:	Mild	3	3
	Moderate	0	0
	Severe	0	0
Edema:	Mild	1	1
	Moderate	2	2
	Severe	2	2
Induration:	Mild	1	1
	Moderate	0	0
	Severe	0	0
Bruising:	Mild	1	1
	Moderate	2	2
	Severe	0	0